newsfilter
← Latest News
GlobeNewswire·

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

GLSI
  • Greenwich LifeSciences (NASDAQ: GLSI) announced two abstracts accepted for presentation at the AACR Annual Meeting 2026, including two corresponding posters.
  • The AACR 2026 conference is scheduled for April 17-22, 2026, with abstract titles published on March 17, 2026.
  • CEO Snehal Patel stated one abstract will be the first co-authored by the Company & the full Steering Committee of FLAMINGO-01.
  • The FLAMINGO-01 Phase III trial has screened over 1,000 patients at a rate of ~600 per year, with the 250-patient non-HLA-A*02 arm fully enrolled.
  • Preliminary analysis of the non-HLA-A*02 arm after the Primary Immunization Series (PIS) shows an ~80% reduction in recurrence rates.
  • GLSI-100 treatment involves a PIS of 6 injections over 6 months followed by 5 booster injections every 6 months to maintain immune response.
  • The observed 80% recurrence reduction in preliminary FLAMINGO-01 data trends similarly to Phase IIb results, which exceeded the 20-50% reduction seen with other approved products.
  • Phase IIb trial data for HLA-A*02 patients showed an 80% or greater reduction in metastatic breast cancer recurrence over 5 years of follow-up.
  • FLAMINGO-01 (NCT05232916) is a double-blinded Phase III trial led by Baylor College of Medicine targeting HER2-positive breast cancer patients with residual disease or high-risk pathologic complete response.
  • The trial plans to randomize ~500 HLA-A*02 patients to GLSI-100 or placebo, with an additional 250 patients of other HLA types treated with GLSI-100.
  • The study design aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, requiring 28 events for final analysis.
  • Greenwich LifeSciences is developing GLSI-100, a 9-amino acid transmembrane peptide of the HER2 protein, to prevent breast cancer recurrences.
  • Forward-looking statements in the release are subject to risks & uncertainties, with actual results potentially differing from expectations.